CR20210207A - Inhibidores de la replicación del virus de la inmunodeficiencia humana - Google Patents
Inhibidores de la replicación del virus de la inmunodeficiencia humanaInfo
- Publication number
- CR20210207A CR20210207A CR20210207A CR20210207A CR20210207A CR 20210207 A CR20210207 A CR 20210207A CR 20210207 A CR20210207 A CR 20210207A CR 20210207 A CR20210207 A CR 20210207A CR 20210207 A CR20210207 A CR 20210207A
- Authority
- CR
- Costa Rica
- Prior art keywords
- immunodeficiency virus
- human immunodeficiency
- inhibitors
- virus replication
- hiv
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 230000029812 viral genome replication Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se definen compuestos de Fórmula I, incluidas las sales farmacéuticamente aceptables de los mismos, y composiciones y procedimientos para tratar la infección por el virus de la inmunodeficiencia humana (VIH).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862749818P | 2018-10-24 | 2018-10-24 | |
PCT/IB2019/059020 WO2020084492A1 (en) | 2018-10-24 | 2019-10-22 | Inhibitors of human immunodeficiency virus replication |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210207A true CR20210207A (es) | 2021-09-02 |
Family
ID=68344933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210207A CR20210207A (es) | 2018-10-24 | 2019-10-22 | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
Country Status (22)
Country | Link |
---|---|
US (2) | US11541055B2 (es) |
EP (1) | EP3870577A1 (es) |
JP (1) | JP7398448B2 (es) |
KR (1) | KR20210084508A (es) |
CN (1) | CN113195475A (es) |
AR (1) | AR116798A1 (es) |
AU (1) | AU2019364739B2 (es) |
BR (1) | BR112021007362A2 (es) |
CA (1) | CA3117289A1 (es) |
CL (1) | CL2021001025A1 (es) |
CO (1) | CO2021004679A2 (es) |
CR (1) | CR20210207A (es) |
DO (1) | DOP2021000062A (es) |
EA (1) | EA202190854A1 (es) |
IL (1) | IL282240A (es) |
MA (1) | MA53973A (es) |
MX (1) | MX2021004593A (es) |
PE (1) | PE20211781A1 (es) |
PH (1) | PH12021550813A1 (es) |
SG (1) | SG11202103560YA (es) |
TW (1) | TWI824041B (es) |
WO (1) | WO2020084492A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7307747B2 (ja) * | 2018-04-11 | 2023-07-12 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤としての4-オキソ-3,4-ジヒドロキナゾリン化合物 |
CN113195475A (zh) * | 2018-10-24 | 2021-07-30 | Viiv保健英国第五有限公司 | 人免疫缺陷病毒复制的抑制剂 |
TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Viiv醫療保健英國(No 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
EP4041729B1 (en) * | 2019-10-08 | 2023-09-27 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
US20230059640A1 (en) | 2019-11-28 | 2023-02-23 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
UY38982A (es) | 2019-12-09 | 2021-06-30 | Viiv Healthcare Co | Composiciones farmacéuticas |
WO2023062559A1 (en) | 2021-10-13 | 2023-04-20 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4773969B2 (ja) | 2003-10-08 | 2011-09-14 | イーライ リリー アンド カンパニー | 脂質代謝異常の治療ための化合物及び方法 |
CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
JP2012201642A (ja) * | 2011-03-25 | 2012-10-22 | Tsutomu Takeuchi | 1−フェニルピロリジン−2,5−ジオン誘導体を有効成分とするbaffの結合阻害剤 |
US9540343B2 (en) | 2011-07-06 | 2017-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
PL2943493T3 (pl) | 2013-01-09 | 2017-12-29 | Gilead Sciences, Inc. | Związki terapeutyczne do leczenia zakażeń wirusowych |
TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
NZ631762A (en) | 2013-01-09 | 2017-02-24 | Gilead Sciences Inc | 5-membered heteroaryls and their use as antiviral agents |
TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
WO2016033009A1 (en) * | 2014-08-27 | 2016-03-03 | Bristol-Myers Squibb Company | Imidazo[1,2-a]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication |
NZ729150A (en) * | 2014-08-29 | 2018-02-23 | Gilead Sciences Inc | Antiretroviral agents |
EP3597646B1 (en) | 2016-08-19 | 2023-06-21 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
EP3752495B1 (en) | 2018-02-15 | 2023-07-19 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
CN112055712B (zh) | 2018-02-16 | 2023-07-14 | 吉利德科学公司 | 用于制备可用于治疗逆转录病毒科病毒感染的治疗性化合物的方法和中间体 |
JP7307747B2 (ja) * | 2018-04-11 | 2023-07-12 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤としての4-オキソ-3,4-ジヒドロキナゾリン化合物 |
EP3833436A1 (en) | 2018-08-09 | 2021-06-16 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
EP3849982A1 (en) | 2018-09-14 | 2021-07-21 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
WO2020058844A1 (en) | 2018-09-20 | 2020-03-26 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
FR3086760A1 (fr) | 2018-10-02 | 2020-04-03 | Institut Mines Telecom | Procede d'evaluation de la resistance mecanique d'un echantillon de tissu biologique |
EP3870576B1 (en) | 2018-10-24 | 2024-01-24 | VIIV Healthcare UK (No.5) Limited | Bezopyrazole derivatives as inhibitors of human immunodeficiency virus replication |
CN113195475A (zh) * | 2018-10-24 | 2021-07-30 | Viiv保健英国第五有限公司 | 人免疫缺陷病毒复制的抑制剂 |
WO2020084480A1 (en) | 2018-10-25 | 2020-04-30 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
EP3873607B1 (en) | 2018-10-29 | 2023-11-29 | VIIV Healthcare UK (No.5) Limited | Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication |
US20210395248A1 (en) | 2018-11-05 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
US20210379071A1 (en) | 2018-11-05 | 2021-12-09 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
UY38559A (es) | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
US11429555B2 (en) | 2019-02-26 | 2022-08-30 | Apple Inc. | Coprocessors with bypass optimization, variable grid architecture, and fused vector operations |
CA3078001A1 (en) | 2019-04-11 | 2020-10-15 | Goli Nutrition Inc. | Apple cider vinegar nutritional supplement |
EP3962603A1 (en) | 2019-04-30 | 2022-03-09 | ViiV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
PE20220510A1 (es) | 2019-06-19 | 2022-04-07 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de inmunodeficiencia humana |
EP4038064B1 (en) | 2019-10-01 | 2024-02-21 | VIIV Healthcare UK (No.5) Limited | N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication |
WO2021064571A1 (en) | 2019-10-01 | 2021-04-08 | VIIV Healthcare UK (No.5) Limited | N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication |
TW202128648A (zh) | 2019-10-04 | 2021-08-01 | 英商Viiv醫療保健英國(No 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
EP4114527A1 (en) | 2020-03-06 | 2023-01-11 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
-
2019
- 2019-10-22 CN CN201980085915.8A patent/CN113195475A/zh active Pending
- 2019-10-22 MA MA053973A patent/MA53973A/fr unknown
- 2019-10-22 MX MX2021004593A patent/MX2021004593A/es unknown
- 2019-10-22 PE PE2021000571A patent/PE20211781A1/es unknown
- 2019-10-22 CA CA3117289A patent/CA3117289A1/en active Pending
- 2019-10-22 JP JP2021522518A patent/JP7398448B2/ja active Active
- 2019-10-22 BR BR112021007362-0A patent/BR112021007362A2/pt unknown
- 2019-10-22 TW TW108138086A patent/TWI824041B/zh active
- 2019-10-22 CR CR20210207A patent/CR20210207A/es unknown
- 2019-10-22 EA EA202190854A patent/EA202190854A1/ru unknown
- 2019-10-22 WO PCT/IB2019/059020 patent/WO2020084492A1/en unknown
- 2019-10-22 KR KR1020217015003A patent/KR20210084508A/ko active Search and Examination
- 2019-10-22 SG SG11202103560YA patent/SG11202103560YA/en unknown
- 2019-10-22 US US16/762,209 patent/US11541055B2/en active Active
- 2019-10-22 EP EP19794683.3A patent/EP3870577A1/en active Pending
- 2019-10-22 AR ARP190103016A patent/AR116798A1/es unknown
- 2019-10-22 AU AU2019364739A patent/AU2019364739B2/en active Active
-
2021
- 2021-04-08 PH PH12021550813A patent/PH12021550813A1/en unknown
- 2021-04-09 DO DO2021000062A patent/DOP2021000062A/es unknown
- 2021-04-11 IL IL282240A patent/IL282240A/en unknown
- 2021-04-14 CO CONC2021/0004679A patent/CO2021004679A2/es unknown
- 2021-04-22 CL CL2021001025A patent/CL2021001025A1/es unknown
-
2022
- 2022-09-30 US US17/957,569 patent/US20230109662A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11541055B2 (en) | 2023-01-03 |
CL2021001025A1 (es) | 2021-11-05 |
PH12021550813A1 (en) | 2021-10-04 |
CA3117289A1 (en) | 2020-04-30 |
MA53973A (fr) | 2022-02-09 |
TW202031261A (zh) | 2020-09-01 |
JP2022505841A (ja) | 2022-01-14 |
US20230109662A1 (en) | 2023-04-06 |
AR116798A1 (es) | 2021-06-16 |
CN113195475A (zh) | 2021-07-30 |
WO2020084492A1 (en) | 2020-04-30 |
EA202190854A1 (ru) | 2021-08-17 |
SG11202103560YA (en) | 2021-05-28 |
AU2019364739A1 (en) | 2021-05-20 |
BR112021007362A2 (pt) | 2021-07-20 |
TWI824041B (zh) | 2023-12-01 |
IL282240A (en) | 2021-05-31 |
CO2021004679A2 (es) | 2021-04-30 |
US20200360384A1 (en) | 2020-11-19 |
PE20211781A1 (es) | 2021-09-08 |
DOP2021000062A (es) | 2021-09-15 |
EP3870577A1 (en) | 2021-09-01 |
KR20210084508A (ko) | 2021-07-07 |
JP7398448B2 (ja) | 2023-12-14 |
MX2021004593A (es) | 2021-06-15 |
AU2019364739B2 (en) | 2022-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021550813A1 (en) | Inhibitors of human immunodeficiency virus replication | |
UY37710A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
MY174224A (en) | Hepatitis b virus surface antigen inhibitor | |
EA202090530A1 (ru) | Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич | |
UA118149C2 (uk) | Інгібітор jak | |
BR112017022544A2 (pt) | ?composto, composição, e, método para tratamento de infecção por hiv?. | |
TR201909152T4 (tr) | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımı. | |
BR112017022605A2 (pt) | ?composto, composição, e, método para tratamento de infecção por hiv?. | |
PH12018501001A1 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
MX2017010506A (es) | Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales. | |
PH12019501198A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
PH12018501712A1 (en) | Methods for treatment and prophylaxis of hiv and aids | |
CR20210664A (es) | Inhibidores de la replicación del virus de inmunodeficiencia humana | |
EA201170537A1 (ru) | Ингибиторы вич-интегразы | |
UY38559A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
WO2019244066A3 (en) | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | |
PH12016502039A1 (en) | Potent and selective inhibitors of hepatitis c virus | |
SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
MX2022009871A (es) | Compuestos tetraciclicos para tratar la infeccion por el virus de la inmunodeficiencia humana (vih). | |
MX2022012881A (es) | Inhibidores de replicacion del virus de inmunodeficiencia humana. | |
MX2022011016A (es) | Inhibidores de la replicacion del virus de inmunodeficiencia humana. | |
MX2021009584A (es) | Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih). | |
BR112018002681A2 (pt) | ?composto, composição, e, método para tratamento de infecção por hiv? |